Collectively, our findings reveal crucial crosstalk between m6A and histone modifications in TMZ resistance and emphasize the therapeutic potential of targeting the SOX4/EZH2/METTL3 axis for the treatment of GBM. This evidence concerns the gene EZH2 and glioblastoma.